https://www.live-feeds.com/feed/detailed-data-confirm-moderna-and-merck-cancer-vaccine-met-key-endpoints-in-melanoma-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/detailed-data-confirm-moderna-and-merck-cancer-vaccine-met-key-endpoints-in-melanoma-trialhttps://www.live-feeds.com/feed/detailed-data-confirm-moderna-and-merck-cancer-vaccine-met-key-endpoints-in-melanoma-trial#u155378Mon, 26 Oct 2026 07:20:34 +0000Detailed phase 3 trial results confirm that the individualized mRNA cancer vaccine intismeran autogene, combined with pembrolizumab, significantly reduced the risk of melanoma recurrence or death compared to pembrolizumab alone. Six melanoma specialists affirmed the findings as a clinically meaningful advancement for patients treated after surgery. While the data surpassed analyst predictions, public sharing of preliminary metrics on social media previously triggered sharp stock volatility and a drop in Moderna shares due to valuation concerns. The therapy targets unique tumor neoantigens to p